fda approved drugs and natural products from spectrum chemical collection Search Results


broad spectrum nucleoside analogue inhibitor remdesivir  (Gilead Sciences)
99
Gilead Sciences broad spectrum nucleoside analogue inhibitor remdesivir
Broad Spectrum Nucleoside Analogue Inhibitor Remdesivir, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fda+approved+drugs+and+natural+products+from+spectrum+chemical+collection/VEKLURY/pmc08349736-19-12-15
Average 99 stars, based on 1 article reviews
broad spectrum nucleoside analogue inhibitor remdesivir - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
fda approved biotyper maldi tof mass spectrometry system  (Bruker Corporation)
96
Bruker Corporation fda approved biotyper maldi tof mass spectrometry system
Figure 6. Assessing Bactericidal Effects of 18NC75-10P-1IL in vivo and in vitro. <t>a)</t> <t>MALDI-TOF</t> mass <t>spectrometry</t> analysis displaying the bacteria identity in pus collected from the outer orifices of anorectal fistula tracts in rats (n = 4). b) Representative Gram stain images of tissue sections from rat anorectal fistulas injected with 18NC75 or 18NC75-10P-1IL at D0, D2, and D7 post-injection. Arrowheads indicate Gram+ bacteria stained in purple. c) Quantitative analyses of Gram+ bacteria count in areas surrounding the fistula tracts at D0, D2, and D7 post-injection with 18NC75 or 18NC75-10P-1IL (n = 10). d) Images of blood agar plates illustrating the robust bactericidal effect of 18NC75-10P-1IL against selected patient-derived bacteria, including S. haemolyticus, S. epidermidis, MRSA, and E. cloacae, tested in direct contact with the hydrogel compared to the control. Data presented as mean ± s.e.m.; statistical significance determined by two-way ANOVA with Tukey’s multiple-comparison test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Fda Approved Biotyper Maldi Tof Mass Spectrometry System, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fda+approved+drugs+and+natural+products+from+spectrum+chemical+collection/MALDI+Biotyper+Systems/pm39950851-454-9-15
Average 96 stars, based on 1 article reviews
fda approved biotyper maldi tof mass spectrometry system - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
nih-cc  (Biomol GmbH)
90
Biomol GmbH nih-cc
Figure 6. Assessing Bactericidal Effects of 18NC75-10P-1IL in vivo and in vitro. <t>a)</t> <t>MALDI-TOF</t> mass <t>spectrometry</t> analysis displaying the bacteria identity in pus collected from the outer orifices of anorectal fistula tracts in rats (n = 4). b) Representative Gram stain images of tissue sections from rat anorectal fistulas injected with 18NC75 or 18NC75-10P-1IL at D0, D2, and D7 post-injection. Arrowheads indicate Gram+ bacteria stained in purple. c) Quantitative analyses of Gram+ bacteria count in areas surrounding the fistula tracts at D0, D2, and D7 post-injection with 18NC75 or 18NC75-10P-1IL (n = 10). d) Images of blood agar plates illustrating the robust bactericidal effect of 18NC75-10P-1IL against selected patient-derived bacteria, including S. haemolyticus, S. epidermidis, MRSA, and E. cloacae, tested in direct contact with the hydrogel compared to the control. Data presented as mean ± s.e.m.; statistical significance determined by two-way ANOVA with Tukey’s multiple-comparison test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Nih Cc, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fda+approved+drugs+and+natural+products+from+spectrum+chemical+collection/nih+cc/pmc06945546-127-9-14
Average 90 stars, based on 1 article reviews
nih-cc - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
microsource spectrum  (MicroSource Discovery Systems)
90
MicroSource Discovery Systems microsource spectrum
Figure 6. Assessing Bactericidal Effects of 18NC75-10P-1IL in vivo and in vitro. <t>a)</t> <t>MALDI-TOF</t> mass <t>spectrometry</t> analysis displaying the bacteria identity in pus collected from the outer orifices of anorectal fistula tracts in rats (n = 4). b) Representative Gram stain images of tissue sections from rat anorectal fistulas injected with 18NC75 or 18NC75-10P-1IL at D0, D2, and D7 post-injection. Arrowheads indicate Gram+ bacteria stained in purple. c) Quantitative analyses of Gram+ bacteria count in areas surrounding the fistula tracts at D0, D2, and D7 post-injection with 18NC75 or 18NC75-10P-1IL (n = 10). d) Images of blood agar plates illustrating the robust bactericidal effect of 18NC75-10P-1IL against selected patient-derived bacteria, including S. haemolyticus, S. epidermidis, MRSA, and E. cloacae, tested in direct contact with the hydrogel compared to the control. Data presented as mean ± s.e.m.; statistical significance determined by two-way ANOVA with Tukey’s multiple-comparison test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Microsource Spectrum, supplied by MicroSource Discovery Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fda+approved+drugs+and+natural+products+from+spectrum+chemical+collection/microsource+spectrum/pmc04165891-59-14-25
Average 90 stars, based on 1 article reviews
microsource spectrum - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
spectrum collection compound library  (MicroSource Discovery Systems)
90
MicroSource Discovery Systems spectrum collection compound library
Figure 6. Assessing Bactericidal Effects of 18NC75-10P-1IL in vivo and in vitro. <t>a)</t> <t>MALDI-TOF</t> mass <t>spectrometry</t> analysis displaying the bacteria identity in pus collected from the outer orifices of anorectal fistula tracts in rats (n = 4). b) Representative Gram stain images of tissue sections from rat anorectal fistulas injected with 18NC75 or 18NC75-10P-1IL at D0, D2, and D7 post-injection. Arrowheads indicate Gram+ bacteria stained in purple. c) Quantitative analyses of Gram+ bacteria count in areas surrounding the fistula tracts at D0, D2, and D7 post-injection with 18NC75 or 18NC75-10P-1IL (n = 10). d) Images of blood agar plates illustrating the robust bactericidal effect of 18NC75-10P-1IL against selected patient-derived bacteria, including S. haemolyticus, S. epidermidis, MRSA, and E. cloacae, tested in direct contact with the hydrogel compared to the control. Data presented as mean ± s.e.m.; statistical significance determined by two-way ANOVA with Tukey’s multiple-comparison test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Spectrum Collection Compound Library, supplied by MicroSource Discovery Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fda+approved+drugs+and+natural+products+from+spectrum+chemical+collection/spectrum+collection+compound+library/pmc03082451-988-25-32
Average 90 stars, based on 1 article reviews
spectrum collection compound library - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
investigational device exemption for spectral medical pmx  (Spectrum Medical Inc)
90
Spectrum Medical Inc investigational device exemption for spectral medical pmx
Figure 6. Assessing Bactericidal Effects of 18NC75-10P-1IL in vivo and in vitro. <t>a)</t> <t>MALDI-TOF</t> mass <t>spectrometry</t> analysis displaying the bacteria identity in pus collected from the outer orifices of anorectal fistula tracts in rats (n = 4). b) Representative Gram stain images of tissue sections from rat anorectal fistulas injected with 18NC75 or 18NC75-10P-1IL at D0, D2, and D7 post-injection. Arrowheads indicate Gram+ bacteria stained in purple. c) Quantitative analyses of Gram+ bacteria count in areas surrounding the fistula tracts at D0, D2, and D7 post-injection with 18NC75 or 18NC75-10P-1IL (n = 10). d) Images of blood agar plates illustrating the robust bactericidal effect of 18NC75-10P-1IL against selected patient-derived bacteria, including S. haemolyticus, S. epidermidis, MRSA, and E. cloacae, tested in direct contact with the hydrogel compared to the control. Data presented as mean ± s.e.m.; statistical significance determined by two-way ANOVA with Tukey’s multiple-comparison test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Investigational Device Exemption For Spectral Medical Pmx, supplied by Spectrum Medical Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fda+approved+drugs+and+natural+products+from+spectrum+chemical+collection/investigational+device+exemption+for+spectral+medical+pmx/pm32445226-37-10-8
Average 90 stars, based on 1 article reviews
investigational device exemption for spectral medical pmx - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
the spectrum collection  (MicroSource Discovery Systems)
90
MicroSource Discovery Systems the spectrum collection
Figure 6. Assessing Bactericidal Effects of 18NC75-10P-1IL in vivo and in vitro. <t>a)</t> <t>MALDI-TOF</t> mass <t>spectrometry</t> analysis displaying the bacteria identity in pus collected from the outer orifices of anorectal fistula tracts in rats (n = 4). b) Representative Gram stain images of tissue sections from rat anorectal fistulas injected with 18NC75 or 18NC75-10P-1IL at D0, D2, and D7 post-injection. Arrowheads indicate Gram+ bacteria stained in purple. c) Quantitative analyses of Gram+ bacteria count in areas surrounding the fistula tracts at D0, D2, and D7 post-injection with 18NC75 or 18NC75-10P-1IL (n = 10). d) Images of blood agar plates illustrating the robust bactericidal effect of 18NC75-10P-1IL against selected patient-derived bacteria, including S. haemolyticus, S. epidermidis, MRSA, and E. cloacae, tested in direct contact with the hydrogel compared to the control. Data presented as mean ± s.e.m.; statistical significance determined by two-way ANOVA with Tukey’s multiple-comparison test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
The Spectrum Collection, supplied by MicroSource Discovery Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fda+approved+drugs+and+natural+products+from+spectrum+chemical+collection/spectrum+collection/pm31562564-159-33-38
Average 90 stars, based on 1 article reviews
the spectrum collection - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Figure 6. Assessing Bactericidal Effects of 18NC75-10P-1IL in vivo and in vitro. a) MALDI-TOF mass spectrometry analysis displaying the bacteria identity in pus collected from the outer orifices of anorectal fistula tracts in rats (n = 4). b) Representative Gram stain images of tissue sections from rat anorectal fistulas injected with 18NC75 or 18NC75-10P-1IL at D0, D2, and D7 post-injection. Arrowheads indicate Gram+ bacteria stained in purple. c) Quantitative analyses of Gram+ bacteria count in areas surrounding the fistula tracts at D0, D2, and D7 post-injection with 18NC75 or 18NC75-10P-1IL (n = 10). d) Images of blood agar plates illustrating the robust bactericidal effect of 18NC75-10P-1IL against selected patient-derived bacteria, including S. haemolyticus, S. epidermidis, MRSA, and E. cloacae, tested in direct contact with the hydrogel compared to the control. Data presented as mean ± s.e.m.; statistical significance determined by two-way ANOVA with Tukey’s multiple-comparison test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Catheter Injectable Multifunctional Biomaterial for the Treatment of Infected Enterocutaneous Fistulas.

doi: 10.1002/advs.202414642

Figure Lengend Snippet: Figure 6. Assessing Bactericidal Effects of 18NC75-10P-1IL in vivo and in vitro. a) MALDI-TOF mass spectrometry analysis displaying the bacteria identity in pus collected from the outer orifices of anorectal fistula tracts in rats (n = 4). b) Representative Gram stain images of tissue sections from rat anorectal fistulas injected with 18NC75 or 18NC75-10P-1IL at D0, D2, and D7 post-injection. Arrowheads indicate Gram+ bacteria stained in purple. c) Quantitative analyses of Gram+ bacteria count in areas surrounding the fistula tracts at D0, D2, and D7 post-injection with 18NC75 or 18NC75-10P-1IL (n = 10). d) Images of blood agar plates illustrating the robust bactericidal effect of 18NC75-10P-1IL against selected patient-derived bacteria, including S. haemolyticus, S. epidermidis, MRSA, and E. cloacae, tested in direct contact with the hydrogel compared to the control. Data presented as mean ± s.e.m.; statistical significance determined by two-way ANOVA with Tukey’s multiple-comparison test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: Isolated colonies exhibiting unique morphologies were identified using the FDA-approved Biotyper MALDI-TOF mass spectrometry system (Bruker Scientific, Billerica, MA, USA) following the manufacturer’s protocol.

Techniques: In Vivo, In Vitro, Mass Spectrometry, Bacteria, Staining, Injection, Derivative Assay, Control, Comparison